Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S C Oh

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
British Journal of Cancer|February 24, 2005
Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancerS C Oh, K H Park, I K Choi, et al.
British Journal of Cancer|May 3, 2007
A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancerS C Oh, H Y Sur, H J Sung, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2020
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 studyE Van Cutsem, K Muro, D Cunningham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2016
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinomaS-E Al-Batran, E Van Cutsem, S C Oh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 14, 2018
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapyY-K Kang, M-H Ryu, S H Park, et al.
ESMO Open|August 27, 2022
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort AD V T Catenacci, Y-K Kang, H H Yoon, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
British Journal of Cancer|February 24, 2005
Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancerS C Oh, K H Park, I K Choi, et al.
British Journal of Cancer|May 3, 2007
A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancerS C Oh, H Y Sur, H J Sung, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2020
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 studyE Van Cutsem, K Muro, D Cunningham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2016
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinomaS-E Al-Batran, E Van Cutsem, S C Oh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 14, 2018
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapyY-K Kang, M-H Ryu, S H Park, et al.
ESMO Open|August 27, 2022
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort AD V T Catenacci, Y-K Kang, H H Yoon, et al.
Pageof 2